GGTI298
目录号: PL10886
CAS No. :180977-44-0
商品编号 规格 价格 会员价 是否有货 数量
PL10886-1mg 1mg ¥1446.00 请登录
PL10886-5mg 5mg ¥2893.00 请登录
PL10886-10mg 10mg ¥4500.00 请登录
PL10886-25mg 25mg ¥8840.00 请登录
PL10886-50mg 50mg ¥12054.00 请登录
PL10886-10mM*1mLinDMSO 10mM*1mLinDMSO ¥3052.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
GGTI298
中文别名
GGTI-298
英文名称
GGTI298
英文别名
L-Leucine,N-[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)benzoyl]-, methylester;GGTI 298;GGTI-298;methyl (2S)-2-[[4-[[(2R)-2-amino-3-sulfanylpropyl]amino]-2-naphthalen-1-ylbenzoyl]amino]-4-methylpentanoate,2,2,2-trifluoroacetic acid;L-Leucine,N-[4-[(2-amino-3-mercaptopropyl)amino]-2-(1-naphthalenyl)benzoyl]-, methylester, (R)-;N-[4-[2(R)-AMino-3-Mercaptopropyl]aMino-2-(1-naphthalenyl)benzoyl]-L-leucineMethylestertrifluoroacetatesalt;GGTI298 (CF3CO2H)salt;GGTI-298 trifluoroacetate salt;N-4-[2(R)-AMINO-3-MERCAPTOPROPYL]AMINO-2-NAPHTHYLBENZOYL-(L)-LEUCINE METHYL ESTER, TFA;N-[[4-(2-(R)-AMINO-3-MERCAPTOPROPYL)AMINO]-2-NAPHTHYLBENZOYL]LEUCINE METHYL ESTER TRIFLUOROACETATE SALT;N-[[4-(2-(R)-Amino-3-mercaptopropyl)amino]-2-naphthylbenzoyl]leucine methyl ester trifluoroacetate salt;GGTI298 Trifluoroacetate;GGTI298 (Trifluoroacetate);GGTI 298 TFA salt;GGTI 298 trifluoroacetate salt hydrate;AOB33796;BCP24853;s7466;GGTI298 trifluoroacetate salt hydrate;GGTI 298 trifluoroacetate salt hydrate, >=90% (HPLC), film;(S)-methyl 2-(4-(((R)-2-amino-3-mercaptopropyl)amino)-2-(naphthalen-1-yl)benzamido)-4-methyl;GGTI298
Cas No.
180977-44-0
分子式
C29H34F3N3O5S
分子量
593.66
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
GGTI298 是有效的 GGTase I 抑制剂,能够抑制 geranylgeranylated Rap1A 的过程,对 farnesylated Ha-Ras 的过程也有一定影响,在体内,IC50 值分别为 3 和 > 20 μM。
生物活性
GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC 50 values of 3 and > 20 μM in vivo, respectively.
性状
Solid
IC50 & Target[1][2]
IC50: 3 μM (Rap1A, in vivo), > 20 μM (Ha-Ras, in vivo)
体外研究(In Vitro)
Both RhoA inhibitor (GGTI298) and ROCK inhibitor (H1152) significantly reduce cAMP agonist-stimulated IK(ap), whereas the latter additionally reduces colocalization of KCNN4c with the apical membrane marker wheat germ agglutinin in T84WT cells. Knockdown of DR4 abolishes NF-κB activation, leading to sensitization of DR5-dependent apoptosis induced by the combination of GGTI298 and TRAIL. GGTI298/TRAIL activates NF-κB and inhibits Akt. knockdown of DR5, preventes GGTI298/TRAIL-induced IκBα and p-Akt reduction, suggesting that DR5 mediates reduction of IκBα and p-Akt induced by GGTI298/TRAIL. In contrast, DR4 knockdown further facilitates GGTI298/TRAIL-induced p-Akt reduction. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
The vivo mouse ileal loop experiments show fluid accumulation is reduced in a dose-dependent manner by TRAM-34, GGTI298, or H1152 when injected together with cholera toxin into the loop. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Sheikh IA, et al. The Epac1 signaling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrhea. J Biol Chem. 2013 Jul 12;288(28):20404-15
[2]. Chen S, et al. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Mol Cancer. 2010 Jan 29;9:23.
溶解度数据
In Vitro: DMSO : 100 mg/mL (208.49 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2